Tim Harding Email & Phone Number

New York, New York, Us

Tumor Biology and Epigenetics

During my career transition, I have dedicated my time to enhancing my knowledge and skills in oncology research and drug development. My activities include:--Currently Enrolled in Online Curriculum: "An R Package for Dose-Response Data Analysis Using Logistic Models:"--Webinars in Oncology: Participated in several oncology webinars to stay updated on the latest research and trends.--Antibody Engineering; Attended sessions on antibody development, to enhance my understanding of biologic development of methods and applications.--Keeping up with the Literature: Regularly review scientific literature to stay informed about emerging trends in oncology and related fields.--Method Development in Cell-Based Assays: Concentrated on method development in cell-based assays and comprehending new techniques in drug development.--Networking: Actively networked with professionals in the industry to exchange ideas and stay connected with the community.--Community service with disaster relief efforts

Waltham, Ma, Us

-Led the screening of small molecules and proteomic libraries via CRISPR/Cas9 knockouts to identify essential proteins for AAV titer enhancement.-Developed and optimized gene expression enhancers, including AAV viral particle production, through novel high-throughput assays in both adherent and suspension cell cultures.-Regularly applied flow cytometry, high-resolution imaging, and reporter assays to quantify AAV production.-Mentored and trained colleagues in advanced transfection, viral transduction, cell culture, and flow cytometry techniques.

Waltham, Ma, Us

San Diego, California, Us

Cytokine/Receptor modulation of immune function in GI related disease.Utilized multi-parameter flow cytometry for immunophenotyping human and non-human primate leukocytes from models of Irritable Bowel Syndrome (IBS) and Crohn's disease. Demonstrated development of Flow based cytokine receptor binding assays in human and non-human primate cells.Differentiated and characterized classical and non-classical monocyte cytokine expression as a potential of activation in disease models.Isolated and immunophenotyped T regulatory cells.

New York, New York, Us

Cancer Vaccines and Immunotherapy Group (ORD). Curated and managed a dynamic portfolio of over 20 concurrent immune/non immune cell lines, serving the demands of the CVIT department. Delivered biochemical support in the development of bi-specific antibody modulation in cancer.-Development and characterization of BCMA cell targets for bi-specific vaccine program-Assay development of T cell mediated killing assay post biologic monoclonal antibody priming-CAR-T cell characterization of bi/tri specific antigen stimulation and phenotypic screening expression of proteins from CRISPR manipulated CAR CellsContract Employee, reached maximum contract extensions.

Associate Scientist II, Translational Oncology.Biochemical analysis of the signal transduction pathways stimulated by the small molecule Entrectinib, aNTRK, Ros1, and ALK inhibitor, in the context of specific gene rearrangements and tumor resistance in cancer. -Utilization of 3D models of cancer engineered cell lines for proliferation assays as well as live cell imaging -Isolation of PDX cells for DNA/RNA isolation, NGS library preparation following GLP protocols.-3D cell compound dosing and subsequent biochemical analysis using western blots, protein arrays and in cell westerns to determine mechanisms of cellular tolerance to the drug.-Skilled in isolation and characterization of murine cells from neural, lung and musculature origins.Company was acquired.

Associate Scientist, Discovery OncologySmall Molecule Drug development including target validation and biomarker development in reference to non small cell lung and pancreatic cancers. MOA studies of small molecule inhibitors by construction of cell lines ( 3D culture), transfection of DNA/sh/siRNAs and viral infection.Experienced in phenotypic and biochemical characterization of proliferation, cell cycle, apoptosis, immunoblotting, ELISA (MSD), HTS Screening/Imaging--including in cell western assays/licor and light/fluorescent microscopy. Extensive Small molecule screening with identification of autophagy targets, target validation, MOA and SAR studies.Highly proficient in isolation of primary cells from tissues including lung, pancreas and PBMC.Acquired by Bristol Myers Squibb.

Us

Preclinical and clinical support for ANA773, a toll-like receptor 7 (TLR7) agonist, being developed for the treatment of cancer and hepatitis C virus (HCV) infection.Extraction of PBMC from both human and cyno whole blood for compound characterization by flow cytometry.Immunophenotyping of TLR-7 agonist dosed patients in phase II trials, and agonist dosing schedule studies in non-human primates, with a specific focus on Treg functional activity, and T cell activation markers. Functional assays of cytokine release, multi-parameter flow cytometry and combination ADCC mediated tumor killing studies.Acquired by Roche.

Chapel Hill, Nc, Us

Investigated receptor and non-receptor tyrosine kinase signaling. Characterized the focal adhesion kinase homolog CADTK (Pyk2) signaling events and localized the protein to focal adhesions in smooth muscle cells. Compared and contrasted the signaling mechanisms of PYK2 from FAK from integrins and src family kinases and integrins.Studied signaling events from the EGFR family and chimeric signaling of EGFR. MERTK signaling and differentiation in 32D cells. Immune biology of RPE clearance. Extensive graduate classwork in the Department of Pharmacology.

M.S., Molecular Pathology

Bachelor Of Science (B.S.), Biology/Biological Sciences, General